Filtered By:
Drug: Avandia

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 42 results found since Jan 2013.

N2 Neutrophils, Novel Players in Brain Inflammation After Stroke: Modulation by the PPAR{gamma} Agonist Rosiglitazone Basic Sciences
Conclusions— We present the first evidence of neutrophil reprogramming toward an N2 phenotype in brain inflammation, which can be modulated by activation of the peroxisome proliferator-activated receptor- nuclear receptor. We also show that N2 polarization is associated with an increased neutrophil clearance, thus suggesting that this switch is a crucial event for resolution of inflammation that may participate in neuroprotection.
Source: Stroke - November 25, 2013 Category: Neurology Authors: Cuartero, M. I., Ballesteros, I., Moraga, A., Nombela, F., Vivancos, J., Hamilton, J. A., Corbi, A. L., Lizasoain, I., Moro, M. A. Tags: Basic Sciences Source Type: research

Rosiglitazone Promotes White Matter Integrity and Long-Term Functional Recovery After Focal Cerebral Ischemia Basic Sciences
Conclusions— Rosiglitazone treatment improves long-term white matter integrity after cerebral ischemia, at least, in part, by promoting oligodendrogenesis and facilitating microglial polarization toward the beneficial M2 phenotype.
Source: Stroke - August 24, 2015 Category: Neurology Authors: Han, L., Cai, W., Mao, L., Liu, J., Li, P., Leak, R. K., Xu, Y., Hu, X., Chen, J. Tags: Other Stroke Treatment - Medical Basic Sciences Source Type: research

Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.
CONCLUSIONS: PPAR-γ agonists appear to reduce recurrent stroke and total events of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, and improve insulin sensitivity and the stabilisation of carotid plaques. There is evidence of limited quality that they are well tolerated. However, the conclusions should be interpreted with caution considering the small number and the quality of the included studies. In future, well-designed, double-blind RCTs with large samples are required to assess the efficacy and safety of PPAR-γ agonists in the secondary prevention of stroke and related vascular events in p...
Source: Cochrane Database of Systematic Reviews - October 29, 2015 Category: Journals (General) Authors: Liu J, Wang LN Tags: Cochrane Database Syst Rev Source Type: research

Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.
CONCLUSIONS: Peroxisome proliferator-activated receptor gamma agonists probably reduce recurrent stroke and total events of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, and may improve insulin sensitivity and the stabilisation of carotid plaques. Their effects on adverse events are uncertain. Our conclusions should be interpreted with caution considering the small number and the quality of the included studies. Further well-designed, double-blind RCTs with large samples are required to assess the efficacy and safety of PPAR-γ agonists in the secondary prevention of stroke and related vascular...
Source: Cochrane Database of Systematic Reviews - December 2, 2017 Category: General Medicine Authors: Liu J, Wang LN Tags: Cochrane Database Syst Rev Source Type: research

Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack
CONCLUSIONS: Peroxisome proliferator-activated receptor gamma agonists probably reduce recurrent stroke and total events of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, and may improve insulin sensitivity and the stabilisation of carotid plaques. Their effects on adverse events are uncertain. Our conclusions should be interpreted with caution considering the small number and the quality of the included studies. Further well-designed, double-blind RCTs with large samples are required to assess the efficacy and safety of PPAR-γ agonists in the secondary prevention of stroke and related vascular...
Source: Cochrane Database of Systematic Reviews - January 10, 2023 Category: General Medicine Authors: Jia Liu Lu-Ning Wang Source Type: research

Antidiabetic drugs and stroke risk. Current evidence.
Abstract Cardiovascular disease (CVD) is the major cause of morbidity and mortality for individuals with type 2 diabetes (T2D). In particular, the risk for stroke is twice that of patients without diabetes, and diabetes may be responsible for >8% of first ischemic strokes. Therefore, the way to prevent stroke in these patients has become an important issue. Traditionally, glucose-lowering drugs had not been shown to protect against stroke. Moreover, several antidiabetic drugs (i.e., sulfonylureas, rosiglitazone) have been reported to be associated with increased risks of CVD and stroke. On the contrary, data on...
Source: European Journal of Internal Medicine - September 20, 2017 Category: Internal Medicine Authors: Castilla-Guerra L, Fernandez-Moreno MDC, Leon-Jimenez D, Carmona-Nimo E Tags: Eur J Intern Med Source Type: research

Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
CONCLUSIONS: RSG treatment protects against BBB damage and ameliorates HT in delayed tPA-treated stroke mice by activating PPAR-γ and favoring microglial polarization toward anti-inflammatory phenotype. PMID: 31756041 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - November 21, 2019 Category: Neuroscience Authors: Li Y, Zhu ZY, Lu BW, Huang TT, Zhang YM, Zhou NY, Xuan W, Chen ZA, Wen DX, Yu WF, Li PY Tags: CNS Neurosci Ther Source Type: research

Drug repurposing for immune modulation in acute ischemic stroke.
Abstract Innate immune cells play a dualistic role in the evolution of ischemic brain damage, with classic phenotypes promoting injury, and alternatively activated M2 microglia/macrophages or N2 neutrophils providing tissue remodelling and repair. Recently, a number of drugs commonly used for other indications (i.e., azithromycin, minocycline, bexarotene, rosiglitazone, metformin) was reported to provide neuroprotection in preclinical stroke models by promoting immune polarization towards non-inflammatory, protective phenotypes. Repurposing drugs with a well-established safety profile should allow a reduction in t...
Source: Current Opinion in Pharmacology - December 1, 2015 Category: Drugs & Pharmacology Authors: Amantea D, Bagetta G Tags: Curr Opin Pharmacol Source Type: research

Smurf2‐mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke
Abstract EZH2 plays an important role in stem cell renewal and maintenance by inducing gene silencing via its histone methyltransferase activity. Previously, we showed that EZH2 downregulation enhances neuron differentiation of human mesenchymal stem cells (hMSCs); however, the underlying mechanisms of EZH2‐regulated neuron differentiation are still unclear. Here, we identify Smurf2 as the E3 ubiquitin ligase responsible for the polyubiquitination and proteasome‐mediated degradation of EZH2, which is required for neuron differentiation. A ChIP‐on‐chip screen combined with gene microarray analysis revealed that PPAR...
Source: EMBO Molecular Medicine - March 25, 2013 Category: Molecular Biology Authors: Yung‐Luen Yu, Ruey‐Hwang Chou, Woei‐Cherng Shyu, Shu‐Ching Hsieh, Chen‐Shiou Wu, Shu‐Ya Chiang, Wei‐Jung Chang, Jia‐Ni Chen, Yen‐Ju Tseng, Yu‐Hsuan Lin, Wei Lee, Su‐Peng Yeh, Jennifer L. Hsu, Cheng‐Chieh Yang, Shih‐Chieh Hung, Mi Tags: Research Article Source Type: research

Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
We examined the association between glucose-lowering medications and a broad range of cardiovascular outcomes, and assessed the strength of evidence for these associations.MethodsFor this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications. Cardiovascular outcomes examined included major adverse cardiovascular events, cardiovascular death, myocardial infarction, stroke, heart failure, unstable angina, and atrial fibrillation. For each meta-analysis, we estimat...
Source: The Lancet Diabetes and Endocrinology - January 30, 2020 Category: Endocrinology Source Type: research

Rosiglitazone and Outcomes for Patients with Diabetes and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
CONCLUSIONS: Among patients with type 2 diabetes and CAD in the BARI 2D trial, neither on-treatment nor propensity matched analysis supported an association of rosiglitazone treatment with an increase in major ischemic cardiovascular events. CLINICAL TRIAL REGISTRATION INFORMATION: http://www.clinicaltrials.gov. Identifier: NCT00006305. PMID: 23857320 [PubMed - as supplied by publisher]
Source: Circulation - July 15, 2013 Category: Cardiology Authors: Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber AJ, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL, for the BARI 2D Investigators Tags: Circulation Source Type: research

Rosiglitazone-induced CD36 up-regulation resolves inflammation by PPARγ and 5-LO-dependent pathways.
Abstract PPARγ-achieved neuroprotection in experimental stroke has been explained by the inhibition of inflammatory genes, an action in which 5-LO, Alox5, is involved. In addition, PPARγ is known to promote the expression of CD36, a scavenger receptor that binds lipoproteins and mediates bacterial recognition and also phagocytosis. As phagocytic clearance of neutrophils is a requisite for resolution of the inflammatory response, PPARγ-induced CD36 expression might help to limit inflammatory tissue injury in stroke, an effect in which 5-LO might also be involved. Homogenates, sections, and cellular suspensions w...
Source: Journal of Leukocyte Biology - December 12, 2013 Category: Hematology Authors: Ballesteros I, Cuartero MI, Pradillo JM, de la Parra J, Pérez-Ruiz A, Corbí A, Ricote M, Hamilton JA, Sobrado M, Vivancos J, Nombela F, Lizasoain I, Moro MA Tags: J Leukoc Biol Source Type: research

Cerebral cortical microvascular rarefaction in metabolic syndrome is dependent on insulin resistance and loss of nitric oxide bioavailability
ConclusionsFurther analyses revealed that the maintenance of glycemic control and vascular nitric oxide bioavailability were stronger predictors of cerebral cortical MVD in OZR than was prevention of hypertension, and this may have implications for chronic treatment of CVD risk under stroke‐prone conditions.This article is protected by copyright. All rights reserved.
Source: Microcirculation - May 1, 2015 Category: Research Authors: Paul D. Chantler, Carl D. Shrader, Lawrence E. Tabone, Alexandre C. d'Audiffret, Khumara Huseynova, Steven D. Brooks, Kayla W. Branyan, Kristin A. Grogg, Jefferson C. Frisbee Tags: Original Research Source Type: research